Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00401258 · ClinicalTrials.gov registry record · Phase 4

An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome

A Phase 4 study, sponsored by Mclean Hospital.

Completed
Registry status
Phase 4
Development phase
15
Enrollment target

NCT00401258 is a Phase 4 study that has completed, run by Mclean Hospital. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00401258, a Phase 4 study, has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
Phase 4
Development phase
15 participants
Enrollment target

Study Summary

We hypothesize that duloxetine treatment will be associated with improvement in symptoms of IBS, particularly abdominal pain, in individuals without comorbid major depressive disorder. During this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have been diagnosed with irritable bowel syndrome (IBS) will be treated with open-label duloxetine.

Interventions

  • DRUG duloxetine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2006-11
Est. Completion 2008-02
Phase Phase 4

Sponsor

Mclean Hospital

140 total trials

What the Registry Record Tells You About NCT00401258

The ClinicalTrials.gov registry entry for NCT00401258 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which duloxetine is the first listed.

NCT00401258 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00401258 about?

NCT00401258 is a clinical study titled "An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome". We hypothesize that duloxetine treatment will be associated with improvement in symptoms of IBS, particularly abdominal pain, in individuals without comorbid major depressive disorder. During this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years wh...

What is the current status of trial NCT00401258?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2006-11. Estimated completion is 2008-02.

What interventions are being tested in trial NCT00401258?

The interventions under investigation include: duloxetine (DRUG).

Who is sponsoring clinical trial NCT00401258?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.